These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21167115)

  • 1. Achilles heels and Trojan horses against drug-resistant tumor cells.
    Park K
    J Control Release; 2011 Jan; 149(2):91. PubMed ID: 21167115
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance reversal agents.
    Robert J; Jarry C
    J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929
    [No Abstract]   [Full Text] [Related]  

  • 4. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?
    Bourquin JP; Bornhauser B
    Expert Rev Hematol; 2010 Aug; 3(4):369-72. PubMed ID: 21083025
    [No Abstract]   [Full Text] [Related]  

  • 5. The great multidrug-resistance paradox.
    Chen VY; Rosania GR
    ACS Chem Biol; 2006 Jun; 1(5):271-3. PubMed ID: 17163753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract.
    Fong WF; Wang C; Zhu GY; Leung CH; Yang MS; Cheung HY
    Phytomedicine; 2007 Feb; 14(2-3):160-5. PubMed ID: 16713217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
    J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The inhibition of apoptosis in cancer cells resistant to anticancer drugs].
    Nowak R; Tarasiuk J
    Postepy Biochem; 2004; 50(4):330-43. PubMed ID: 15957528
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
    Sawicka M; Kalinowska M; Skierski J; Lewandowski W
    J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
    Ganta S; Amiji M
    Mol Pharm; 2009; 6(3):928-39. PubMed ID: 19278222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer.
    Li Y; Zhang HB; Huang WL; Li YM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3652-5. PubMed ID: 18502125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance in cancer therapy: role of the microenvironment.
    Galmarini CM; Galmarini FC
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
    Kars MD; Işeri OD; Gunduz U; Molnar J
    Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
    Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reversal of multidrug resistance: an update.
    Kellen JA
    J Exp Ther Oncol; 2003; 3(1):5-13. PubMed ID: 12724854
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.
    Basciani S; Vona R; Matarrese P; Ascione B; Mariani S; Cauda R; Gnessi L; Malorni W; Straface E; Lucia MB
    FEBS Lett; 2007 Dec; 581(30):5897-903. PubMed ID: 18061581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.